Related references
Note: Only part of the references are listed.Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new
Kyle A. Furge et al.
LANCET ONCOLOGY (2010)
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2010)
A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas
Teri N. Kreisl et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
Allan J. Pantuck et al.
CANCER (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Protein kinase C activation and its role in kidney disease
Jun Li et al.
NEPHROLOGY (2006)
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
Michael A. Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
